Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) (Temferon)

适应症

Temferon is being investigated for newly diagnosed, treatment-resistant glioblastoma (GBM). In a first-in-human phase 1 clinical trial, 24 patients with newly diagnosed, treatment-resistant GBM were enrolled.

• Glioblastoma